News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
828,377 Results
Type
Article (85431)
Company Profile (695)
Press Release (742251)
Section
Business (231878)
Career Advice (4106)
Deals (39641)
Drug Delivery (115)
Drug Development (90543)
Employer Resources (194)
FDA (17902)
Job Trends (17269)
News (394897)
Policy (39584)
Tag
Academia (2972)
Alliances (56379)
Alzheimer's disease (1317)
Approvals (17843)
Artificial intelligence (126)
Bankruptcy (394)
Best Places to Work (12428)
Biotechnology (480)
Breast cancer (104)
Cancer (1005)
Career advice (3512)
Cell therapy (254)
Clinical research (71256)
Collaboration (363)
Compensation (166)
COVID-19 (2784)
C-suite (89)
Cystic fibrosis (84)
Data (973)
Diabetes (112)
Diagnostics (6593)
Earnings (94073)
Employer resources (166)
Events (126128)
Executive appointments (264)
FDA (18314)
Funding (309)
Gene therapy (188)
GLP-1 (635)
Government (5021)
Healthcare (20628)
Infectious disease (2851)
Inflammatory bowel disease (120)
Interviews (807)
IPO (17538)
Job creations (5178)
Job search strategy (2855)
Layoffs (482)
Legal (10014)
Lung cancer (159)
Manufacturing (176)
Medical device (14244)
Medtech (14249)
Mergers & acquisitions (22031)
Metabolic disorders (372)
Neuroscience (1579)
NextGen Class of 2024 (7644)
Non-profit (5048)
Northern California (1310)
Obesity (207)
Opinion (244)
Patents (96)
People (64013)
Pharmaceutical (137)
Phase I (21950)
Phase II (30969)
Phase III (23326)
Pipeline (410)
Podcasts (90)
Postmarket research (3533)
Preclinical (9930)
Radiopharmaceuticals (243)
Rare diseases (205)
Real estate (7368)
Regulatory (25803)
Research institute (2638)
Resumes & cover letters (648)
Southern California (1157)
Startups (4272)
United States (12306)
Vaccines (614)
Weight loss (175)
Date
Today (68)
Last 7 days (550)
Last 30 days (3074)
Last 365 days (35192)
2024 (32045)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1261)
Arizona (213)
Asia (49202)
Australia (8680)
California (3004)
Canada (1072)
China (234)
Colorado (95)
Connecticut (123)
Europe (112629)
Florida (348)
Illinois (329)
Indiana (181)
Kansas (103)
Maryland (572)
Massachusetts (2512)
Michigan (139)
Minnesota (245)
New Jersey (872)
New York (848)
North Carolina (784)
Northern California (1310)
Ohio (118)
Pennsylvania (714)
South America (1646)
Southern California (1157)
Texas (386)
Washington State (352)
828,377 Results for "kala bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
KALA BIO to Present at Jefferies 2024 Global Healthcare Conference
KALA BIO, Inc. announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET.
May 29, 2024
·
1 min read
Deals
KALA BIO Announces $12,500,000 Private Placement
KALA BIO, Inc. today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeemable Preferred Stock (the “Series H Preferred Stock”), for aggregate gross proceeds of approximately $12.5 million, before deducting offering expenses.
June 27, 2024
·
4 min read
Press Releases
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
·
12 min read
Business
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
11 min read
Genetown
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
KALA BIO, Inc. (NASDAQ:KALA) today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET.
February 26, 2024
·
1 min read
Business
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
March 29, 2024
·
14 min read
Genetown
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually.
February 6, 2024
·
1 min read
Press Releases
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 6, 2024
·
13 min read
Press Releases
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 8, 2024
·
1 min read
Genetown
Kala Pharmaceuticals Announces Name Change to KALA BIO
Kala Pharmaceuticals, Inc. today announced that it will change its name to KALA BIO, Inc. effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions.
August 2, 2023
·
5 min read
1 of 82,838
Next